CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

United States, New York Icahn School of Medicaine at Mount Sinai **RECRUITING NOW** New York, New York, United States, 10029 Contact: Sundar Jagannath, M.B.B.S    212-241-7873       Principal Investigator: Sundar Jagannath, M.B.B.S          Memorial Sloan Kettering Cancer Center Not yet **RECRUITING NOW** New York, New York, United States, 10065 Contact: Sham Mailankody, MD    646-675-2278       Principal Investigator: Sahm Mailankody, MD          United States, Tennessee Sarah Cannon Research Institution **RECRUITING NOW** Nashville, Tennessee, United States, 37293 Contact: Jesus Berdeja, MD    844-482-4812    asksarah@sarahcannon.com    Principal Investigator: Jesus Berdeja, MD         

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.